[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371099-105":59,"doc-detail-371099-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-multi-centre-performance-evaluation-of-a-commercially-developed-liquid-biopsy-for-the-earlier-detection-of-brain-tumours","A multi-centre performance evaluation of a commercially developed liquid biopsy for the earlier detection of brain tumours","","Delayed diagnosis of brain cancer causes many patients to receive diagnosis only after presenting to emergency care with more severe symptoms or neurological deficits. The EMBRACE international, multi-centre observational study prospectively recruited patients with symptoms potentially associated with brain cancer across seven European sites. Blood serum samples were analysed using the Dxcover Brain Cancer Liquid Biopsy Platform, and test performance was evaluated against diagnostic imaging. Results showed 86% sensitivity and 99% negative predictive value for brain cancer detection.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-multi-centre-performance-evaluation-of-a-commercially-developed-liquid-biopsy-for-the-earlier-detection-of-brain-tumours/371099/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-multi-centre-performance-evaluation-of-a-commercially-developed-liquid-biopsy-for-the-earlier-detection-of-brain-tumours/371099.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-21","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address?","Question",{"text":112,"@type":113},"Delayed brain cancer diagnosis often leads to patients receiving diagnosis only after emergency presentation with more severe symptoms. The study targets earlier detection to improve triage and speed up diagnosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the liquid biopsy tested in the study?",{"text":117,"@type":113},"Prospectively recruited patients with potentially brain-cancer-related symptoms provided blood serum samples. The liquid biopsy result was compared with diagnostic imaging to assess test performance.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the primary diagnostic performance outcomes?",{"text":121,"@type":113},"For the primary objective, the test achieved 86% sensitivity for brain cancer detection and 99% negative predictive value. Combined sensitivity across malignant and benign tumours was 77%.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371099,1790332904,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","ORIGINAL ARTICLE  \nA multi-centre performance evaluation of a commercially developed liquid biopsy for the earlier detection of brain tumours  \nP. M. Brennan1 ∗, J. M. Cameron2, D. Eustace2, H. J. Butler2, A. Sala2, A. Lazarus2, G. Antoniou2, D. S. Palmer2 , 3, E. Gray4, C. Kerrie5, S. McDonald6, P. Black6, S. Sheraz1, I. Adekoya6, A. Jakola7 , 8, A. Denes7, M. D. Jenkinson9, J. Jones9,  \nS. Pendered9, S. Koljenovic10, K. Zwaenepoel10, A. Sieben10, M. Ahmed10, B. Feyen10, R. K. Mathew11, 12, C. Coils11, A. Ismail12, I. Phang13, A. Brown13, S. Patel13, T. Weiss14, P. W. Westarp14, A. Kopp14 & M. J. Baker2 , 15 ∗  \n1Translational Neurosurgery, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh; 2Dxcover Ltd, Royal College Building, Suite RC534, Glasgow; 3Department of Chemistry, University of Strathclyde, Glasgow; 4Freelance Consultant, Edinburgh; 5Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh; 6Emergency Medicine Research Group of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, UK; 7Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, University of Gothenburg, Sahlgrenska Academy, Gothenburg; 8Region Västra Götaland, Sahlgrenska University Hospital, Department of Neurosurgery, Gothenburg, Sweden; 9The Walton Centre, NHS Foundation Trust Liverpool, Liverpool, UK; 10Department of Pathology, Universitair Ziekenhuis Antwerpen (UZA), Antwerp, Belgium; 11Department of Neurosurgery, Leeds Teaching Hospitals NHS Trust, Leeds; 12School of Medicine, University of Leeds, Leeds; 13Lancashire Clinical Research Facility, Royal Preston Hospital, Preston, UK; 14Klinik für Neurologie, Universitätsspital Zürich (USZ), Zurich, Switzerland; 15School of Medicine & Dentistry, University of Lancashire, Preston, UK  \nAvailable online 29 December 2025  \nBackground: Delayed diagnosis of brain cancer leads to two-thirds of patients receiving a diagnosis only after presenting to the emergency department with more severe symptoms or neurological deficits. A simple, rapid, liquid biopsy implemented in primary care could enable more efficient triage of patients with non-specific symptoms potentially related to brain cancer, prioritising patients for urgent brain imaging, and accelerating diagnosis. Patients and methods: Presented is the international, multi-centre, observational Early and tiMely detection of BRAin CancEr (EMBRACE) study. Patients were prospectively recruited across seven sites in Europe, from the United Kingdom, Belgium, Sweden and Switzerland. The target population consisted of patients with symptoms potentially associated with brain cancer. Blood serum samples were analysed by the Dxcover® Brain Cancer Liquid Biopsy Platform. Test performance was assessed by comparison of the liquid biopsy result to diagnostic imaging.  \nResults: Two thousand five hundred and fifty-four patients were enrolled across the seven collection sites; 2324 were deemed eligible and taken forward for test assessment. There were 697 brain tumours in total, of which 395 were malignant, and 1627 non-tumour diagnoses. Overall diagnostic performance for the primary objective was 86% sensitivity for brain cancer detection with 99% negative predictive value (NPV) . Sensitivity for all brain tumours combined (malignant and benign) was 77% . Notably, for the most prevalent and most aggressive brain cancer, glioblastoma, 86% of cases were successfully identified. Additionally, 94% of patients with central nervous system lymphoma, and 90% of brain metastases were predicted correctly as having tumours.  \nConclusions: Existing symptom-based referral pathways are ineffective for the detection of brain cancer, and there isan urgent need for new tests to help with clinical decision making. With a NPV of 99%, the Dxcover Liquid Biopsy test could assist in primary care for efficient stratification of patients toward diagnostic imaging.  \nKey words: brain tumour, brain cancer, liquid biopsy, early detection  \n*Corr","cbCainV3GlKwOaPL","https://ap.wps.com/l/cbCainV3GlKwOaPL","pdf",882901,"English","# Background\n# Patients and methods\n# Results\n## Diagnostic performance\n## Tumour subtype findings\n# Conclusions\n# Introduction","[{\"question\":\"What problem does the study address?\",\"answer\":\"Delayed brain cancer diagnosis often leads to patients receiving diagnosis only after emergency presentation with more severe symptoms. The study targets earlier detection to improve triage and speed up diagnosis.\"},{\"question\":\"How was the liquid biopsy tested in the study?\",\"answer\":\"Prospectively recruited patients with potentially brain-cancer-related symptoms provided blood serum samples. The liquid biopsy result was compared with diagnostic imaging to assess test performance.\"},{\"question\":\"What were the primary diagnostic performance outcomes?\",\"answer\":\"For the primary objective, the test achieved 86% sensitivity for brain cancer detection and 99% negative predictive value. Combined sensitivity across malignant and benign tumours was 77%.\"}]","A multi-centre performance evaluation of a commercially developed liquid biopsy for the earlier detection of brain tumours | PDF",1790191244,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f694f93d8033494a4578f9db3b5c838f.webp",983,1269,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00b9fb82e074689067eaea505922f3a3.webp",982,1268,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b63b39bcb460eadadc830b7c13b6ea97.webp",981,1266,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cff49eda3176f81ce669e11588d9df6b.webp",980,1265]